好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Quantitative Cerebrovascular Reactivity Atlas In Children
Child Neurology and Developmental Neurology
P14 - Poster Session 14 (11:45 AM-12:45 PM)
6-003

To build a functional neuroimaging atlas of cerebrovascular reactivity data in healthy children. 

 

 

Cerebrovascular reactivity (CVR) can be measured by changing arterial blood carbon dioxide (CO2) content and measuring subsequent changes in blood flow. Functional MRI blood oxygen level dependent sequences (BOLD) are used to detect this change. Aberrations in CVR scans can serve as a biomarker of ischemic risk. Data describing the normal range of CVR values in healthy children is needed to allow characterization of observed pathological aberrations in CVR in patient studies. 

Prospective enrollment of healthy children ages 6 to 18. Target N of 40. Two datasets generated within the atlas using two different techniques of administering (CO2): a breath-hold CVR dataset (endogenous stimulus) and a RespirActTM CVR dataset (exogenous). A test of normality is performed on CVR values for each voxel across subjects, with mean and standard deviation calculations. This will allow for generation of a Z-score for each CVR value per voxel in any clinical CVR study. Voxel-wide validation of breath-hold CVR values against the gold standard RespirActTM CVR values will be performed using within subject t-test and between group comparisons. Subgroup analysis based on gender and age will also be performed. 

CVR data for 8 healthy right-handed children is presented (4 female, median age 13, range 9 -14 years). All participants tolerated CVR studies with no side effects reported.  Group datasets acquired passed tests of normality with no significant differences in CVR values between the two methods found. 

CVR neuroimaging studies are performed in patients with a risk of recurrent arterial ischemic strokes, such as those with intracranial arteriopathies and sickle cell disease. Our atlas can provide clinicians with information regarding extent and distribution of CVR abnormalities, allow for stroke risk stratification, and aid in determining the optimal time for surgical and other interventions.

 

Authors/Disclosures
Kenda Alhadid, MD (Massachussets General Hospital)
PRESENTER
Dr. Alhadid has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
William J. Logan, MD (The Hospital for Sick Children) Dr. Logan has nothing to disclose.
Gabrielle A. DeVeber, MD (Hospital for Sick Children) Dr. DeVeber has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for GDEV consultants inc.
No disclosure on file